Katie Heller

December 20, 2022

From the Co-Chairs, December 2022

Reflections on NCI-MATCH and its successor trials; research results in leukemia and breast cancer; and grant renewal preparations
December 20, 2022

Re-Opened Trial: EA9152 for T-cell or B-cell Acute Lymphoblastic Leukemia

This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population
December 20, 2022

Remembering Jerome C. Landry, MD, MBA

In July, the field of radiation oncology lost an expert and pioneer
December 20, 2022

Remembering Edward G. Mansour, MD

In November, the field of breast cancer research lost a revolutionary
December 20, 2022

36 Member Networks and Programs Receive Commendations in 2022 for Outstanding Research Performance

In an annual evaluation, 36 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
December 20, 2022

News in Brief, December 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
October 13, 2022

From the Co-Chairs, October 2022

Research results in breast and kidney cancer; recognition of key colleagues; and a sneak peek of the Fall 2022 Group Meeting
August 16, 2022

From the Co-Chairs, August 2022

President Biden to appoint Dr. Monica Bertagnolli as NCI Director; NCI-MATCH trial data leads to FDA drug approval
August 16, 2022

Institution Spotlight: Penn State Cancer Institute

A Standing Main Member of ECOG-ACRIN since 2002
June 21, 2022

From the Co-Chairs, June 2022

Reflections on the spring conference season, including highlights from the Spring Group Meeting and ASCO's Annual Meeting
June 21, 2022

Now Enrolling: EA9213 for T-Cell Acute Lymphoblastic Leukemia

This single-arm phase II study aims to rid patients of residual disease following initial treatment
June 21, 2022

Trial Spotlight Video: The EA8192 Study Team Discusses Their Trial for High Grade Upper Tract Urothelial Cancer

This study seeks to determine if neoadjuvant treatment with durvalumab and chemotherapy improves patient outcomes over chemotherapy alone